Fluorescent cobalamins and uses thereof
The present invention relates to fluorescent cobalamins and uses of these compounds. More particularly, this invention relates to fluorescent cobalamins that comprise a fluorescent, phosphorescent, luminescent or light-producing compound covalently linked to cobalamin. These fluorescent cobalamins can be used to as diagnostic and prognostic markers (a) to distinguish cancer cells and tissues from healthy cells and tissues, including identifying lymph nodes containing cancer cells, and (b) to determine if an individual will respond positively to chemotherapy using cobalamin-therapeutic bioconjugates.
1. A method for predicting the response of cancer cells to treatment targeting actively dividing cells which comprises:
contacting a cobalamin with cancer cells, said cobalamin having the general formula
where R 1 is CN, OH, OH 2 , CH 3 , 5′-(5′-deoxyadenosyl) or (CH 2 ) p NHC(═S)Y; R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are CONH 2 ; R 8 is CH 2 OH or CH 2 O(C═O)X m Y; R 9 is OH or O(C═O)X m Y; X is a linker having the formula NH(CH 2 ) n NHO(C═O) or NH—(CH 2 ) n —NH; Y is a fluorophore, a phosphorophore, or a chemiluminescent chromophore; m is 0 or 1, n is 0-50 and p is 2-10, with the proviso that at least one of R 1 , R 8 and R 9 groups has Y, wherein said cobalamin fluoresces, phosphoresces or luminesces when illuminated with ultraviolet, visible, or infrared light without cleavage of Y from the cobalamin,
illuminating said cancer cells and
detecting fluorescence, phosphorescence or luminescence of said cancer cells,
wherein a greater fluorescence, phosphorescence or luminescence of said cancer cells compared to non-cancerous cells is indicative that the cancer cells will resvond favorably to said treatment.
2. The method of claim 1 , wherein said treatment is chemotherapy.
3. The method of claim 2 , wherein said chemotherapy is a cobalamin-based chemotherapeutic therapy.
4. The method of claim 1 , wherein said treatment is hormonal therapy.
5. A method for predicting therapeutic response or prognosing patient outcome following therapy of cancer in vivo, ex vivo, or in situ which comprises:
contacting a cobalamin with cancer tissue or cells from said patient, said cobalamin having the general formula
where R 1 is CN, OH, OH 2 , CH 3 , 5′-(5′-deoxyadenosyl) or (CH 2 ) p NHC(═S)Y; R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are CONH 2 ; R 8 is CH 2 OH or CH 2 O(C═O)X m Y; R 9 is OH or O(C═O)X m Y; X is a linker having the formula NH(CH 2 ) n NHO(C═O) or NH—(CH 2 ) n —NH; Y is a fluorophore, a phosphorophore, or a chemiluminescent chromophore; m is 0 or 1, n is 0-50 and p is 2-10, with the proviso that at least one of R 1 , R 8 and R 9 groups has Y, wherein said cobalamin fluoresces, phosphoresces or luminesces when illuminated with ultraviolet, visible, or infrared light without cleavage of Y from the cobalamin,
illuminating said cancer tissue or cells and
detecting fluorescence, phosphorescence or luminescence of said cancer tissue or cells,
wherein a greater fluorescence, phosphorescence or luminescence of said cancer tissue or cells compared to healthy tissue or cells is indicative of favorable therapuetic response or patient outcome to said therapy.
6. The method of claim 5 , wherein the contacting is performed by administering said cobalamin to said patient intravenously, intrathecally, intramuscullarly, intratumorally, intralymphatically or orally.
7. The method of claim 6 , wherein the contacting is performed intraoperatively.
8. The method of claim 7 , wherein the contacting is performed in the course of a clinical pathology evaluation of tissue and cells.